Skip to main content

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Trial Status: Active

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.

Inclusion Criteria

  • Histologically or cytologically confirmed locally advanced or metastatic NSCLC, urothelial carcinoma or HNSCC
  • Progressed after at least 1 line of treatment and no more than 3 lines of treatment
  • At least one measurable lesion as defined by RECIST version 1.1
  • ECOG Performance Status 0 or 1
  • Adequate Bone Marrow Function
  • Adequate Renal Function
  • Adequate Liver Function
  • Resolved acute effects of any prior therapy

Exclusion Criteria

  • Known active uncontrolled or symptomatic CNS metastases.
  • Major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry.
  • Active, uncontrolled infection, including COVID-19
  • Known or suspected hypersensitivity to PF-06939999
  • Inability to consume or absorb study drug

Florida

Miami
University of Miami Miller School of Medicine-Sylvester Cancer Center
Status: ACTIVE

Tennessee

Nashville
Vanderbilt University / Ingram Cancer Center
Status: ACTIVE

Texas

Houston
M D Anderson Cancer Center
Status: ACTIVE

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: ACTIVE

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Pfizer

  • Primary ID C3851001
  • Secondary IDs NCI-2019-01428
  • Clinicaltrials.gov ID NCT03854227